Literature DB >> 28919019

Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity.

Nicolas Skrypek1, Steven Goossens2, Eva De Smedt3, Niels Vandamme4, Geert Berx5.   

Abstract

Epithelial-to-mesenchymal transition (EMT) is a process in which epithelial cells lose their junctions and polarity to gain a motile mesenchymal phenotype. EMT is essential during embryogenesis and adult physiological processes like wound healing, but is aberrantly activated in pathological conditions like fibrosis and cancer. A series of transcription factors (EMT-inducing transcription factor; EMT-TF) regulate the induction of EMT by repressing the transcription of epithelial genes while activating mesenchymal genes through mechanisms still debated. The nuclear interaction of EMT-TFs with larger protein complexes involved in epigenetic genome modulation has attracted recent attention to explain functions of EMT-TFs during reprogramming and cellular differentiation. In this review, we discuss recent advances in understanding the interplay between epigenetic regulators and EMT transcription factors and how these findings could be used to establish new therapeutic approaches to tackle EMT-related diseases.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28919019     DOI: 10.1016/j.tig.2017.08.004

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.639


  90 in total

Review 1.  MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment.

Authors:  Donald W Kufe
Journal:  Carcinogenesis       Date:  2020-09-24       Impact factor: 4.944

2.  An intermediate cell state allows rerouting of cell fate.

Authors:  Xiukun Wang; Jinsong Li
Journal:  J Biol Chem       Date:  2017-11-17       Impact factor: 5.157

3.  EMT in cancer.

Authors:  Thomas Brabletz; Raghu Kalluri; M Angela Nieto; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2018-01-12       Impact factor: 60.716

4.  Prometheus revisited.

Authors:  Kai-Yuan Chen; Xiling Shen; Anna Mae Diehl
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

5.  Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.

Authors:  Tsuyoshi Hata; Hasan Rajabi; Masaaki Yamamoto; Caining Jin; Rehan Ahmad; Yan Zhang; Ling Kui; Wei Li; Yota Yasumizu; Deli Hong; Masaaki Miyo; Masayuki Hiraki; Takahiro Maeda; Yozo Suzuki; Hidekazu Takahashi; Mehmet Samur; Donald Kufe
Journal:  Mol Cancer Ther       Date:  2019-07-15       Impact factor: 6.261

Review 6.  Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer.

Authors:  A J Fritz; N E Gillis; D L Gerrard; P D Rodriguez; D Hong; J T Rose; P N Ghule; E L Bolf; J A Gordon; C E Tye; J R Boyd; K M Tracy; J A Nickerson; A J van Wijnen; A N Imbalzano; J L Heath; S E Frietze; S K Zaidi; F E Carr; J B Lian; J L Stein; G S Stein
Journal:  Genes Chromosomes Cancer       Date:  2019-03-15       Impact factor: 5.006

7.  MiR-137-3p Inhibits Colorectal Cancer Cell Migration by Regulating a KDM1A-Dependent Epithelial-Mesenchymal Transition.

Authors:  Xiaoling Ding; Jie Zhang; Ziqin Feng; Qianru Tang; Xiaorong Zhou
Journal:  Dig Dis Sci       Date:  2020-08-04       Impact factor: 3.199

Review 8.  Epigenetically distinct sister chromatids and asymmetric generation of tumor initiating cells.

Authors:  Yongqing Liu; Laura Siles; Antonio Postigo; Douglas C Dean
Journal:  Cell Cycle       Date:  2018-10-13       Impact factor: 4.534

9.  PCAF, ISX, and BRD4: a maleficent alliance serving lung cancer malignancy.

Authors:  Marc P Stemmler
Journal:  EMBO Rep       Date:  2020-01-07       Impact factor: 8.807

Review 10.  [Wound-induced hair follicle neogenesis: a new perspective on hair follicles regeneration in adult mammals].

Authors:  Pengcheng Liu; Qiuwen Tan; Yanlin Jiang; Qing Lü
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.